Products for cold storage of embryos approved in Europe

Products for cold storage of embryos approved in Europe

Vitrolife has obtained approval in Europe (CE marking) for four new products
within the fertility area. The products are used for so-called vitrification,
rapid freezing and thawing of cleavage embryos (embryos day 2-3 after
fertilization) and of blastocysts (embryos day 5-6 after fertilization). 

The four vitrification products that Vitrolife has obtained approval for are
RapidVit™ Cleave, RapidWarm™ Cleave, RapidVit™ Blast and RapidWarm™ Blast. 

Products for vitrification involve considerable technological progress and open
up new opportunities within IVF treatment. Vitrification involves very rapid
freezing, to prevent the formation of ice crystals that otherwise can cut the
cells apart. In IVF fertilization more than 10 oocytes are often taken from the
woman. A number of these are fertilized. The oocytes that are fertilized but not
put back in the woman can then be kept in cold storage. It has been seen in the
use of the vitrification method that survival increases considerably after cold
storage compared with the method used previously. The chances thereby increase
for the woman to become pregnant without her having to undergo new hormone
treatment and the removal of more oocytes.     

In December 2007 and March 2008 Vitrolife gained its first approvals for these
vitrification products in Canada.



April 8, 2008
Kungsbacka, Sweden 

Magnus Nilsson
CEO




Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share
is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.